146 results
424B3
SYRE
Spyre Therapeutics Inc.
15 May 24
Prospectus supplement
4:06pm
filed with the SEC a definitive proxy statement and other relevant materials.
Following stockholder approval of the Series A Conversion Proposal, each
POS AM
SYRE
Spyre Therapeutics Inc.
26 Mar 24
Prospectus update (post-effective amendment)
6:30pm
;
the cost of clinical trials of any of our programs may be greater than we anticipate;
the quality of our product candidates or other materials necessary … materials that can be inadvertently degraded during transport due to several factors, rendering certain batches unsuitable for trial use for failure
424B3
apwo0lqgc
18 Mar 24
Prospectus supplement
4:06pm
8-K
EX-10.1
3bi ge1eyo
18 Mar 24
Spyre Therapeutics Announces $180 Million Private Placement
8:31am
8-K
EX-10.2
we1edba
18 Mar 24
Spyre Therapeutics Announces $180 Million Private Placement
8:31am
POS AM
f67j rdk3nqpzpn1
14 Mar 24
Prospectus update (post-effective amendment)
4:12pm
POS AM
6axq43w
5 Mar 24
Prospectus update (post-effective amendment)
5:15pm
424B3
fztpw8wg
6 Feb 24
Prospectus supplement
9:37pm
8-K
EX-14.1
u2atmugkg49ips0uyw6h
5 Feb 24
Entry into a Material Definitive Agreement
7:36am